TScan Therapeutics to Participate in SCTC Annual Meeting
TScan Therapeutics, Inc. (Nasdaq: TCRX), a pioneering biotechnology firm, is set to share breakthrough advancements at an upcoming major event. With a dedicated focus on developing T cell receptor-engineered T cell (TCR-T) therapies aimed at tackling various cancers, TScan will display its latest research findings.
Details of the Poster Presentations
Discovering MAGE-A4-specific TCR-T Therapy
The first poster will highlight a significant discovery: a MAGE-A4-specific TCR-T therapy candidate specifically designed for multiplex treatment of solid tumors. This innovative approach is the result of collaborative efforts from esteemed authors such as Rutuja Kulkarni and Akshat Sharma, along with many others. This presentation is scheduled for November 8 from 9:00 a.m. to 7:00 p.m. Central Time at the George R. Brown Convention Center.
Preclinical Models for T-Plex Therapy
Another compelling presentation will delve into preclinical models for T-Plex, a customized multiplexed TCR-T cell therapy that addresses the complexities of intra-tumor antigen and HLA heterogeneity. Led by researchers like Maytal Bowman, this work underscores the intricacies of cancer treatment and is essential viewing for those involved in oncology. It will also take place on November 8 during the same hours and location.
Target Agnostic Platform Development
Additionally, there will be a session focusing on the development of a target agnostic platform that evaluates the reactivity of TCR-T therapies to primary human tissues. This research involves a diverse group of contributors, including Sveta Padmanabhan and Shubhangi Kamalia, and will be presented on November 9 from 9:00 a.m. to 8:30 p.m. Central Time at the same venue. This platform has the potential to transform how TCR-T therapies are assessed before reaching patients.
About TScan Therapeutics
TScan Therapeutics specializes in innovative TCR-T therapies aimed at enhancing treatment outcomes for cancer patients. Their lead candidates, TSC-100 and TSC-101, are being developed to prevent relapse in patients undergoing allogeneic hematopoietic cell transplantation. The company is also expanding its therapeutic repertoire with various candidates targeting solid tumors.
Moreover, TScan continues to enhance its ImmunoBank, a vital collection of therapeutic TCRs. This repository targets a variety of cancer indications, creating customized multiplex TCR-T therapies tailored to individual patient needs.
Contact Information
Should you require further information or wish to discuss collaboration opportunities, please reach out to:
Heather Savelle
TScan Therapeutics, Inc.
VP, Investor Relations
857-399-9840
hsavelle@tscan.com
Maghan Meyers
Argot Partners
212-600-1902
TScan@argotpartners.com
Frequently Asked Questions
What is the main focus of TScan Therapeutics?
TScan Therapeutics focuses on developing TCR-engineered T cell therapies for cancer treatment, aiming for innovative solutions for various malignancies.
Where will the SITC Annual Meeting take place?
The 39th Annual Meeting of the Society for Immunotherapy of Cancer will occur at the George R. Brown Convention Center.
When are the poster presentations scheduled?
The poster presentations are scheduled for November 8 and November 9, with specific time slots allocated for each research topic.
Who are some of the authors involved in these presentations?
Notable authors include Rutuja Kulkarni, Maytal Bowman, and Sveta Padmanabhan, among a collaborative team of researchers.
What breakthroughs will be discussed at the meeting?
The meeting will discuss advancements in TCR-T therapies, preclinical models for multiplex treatments, and a target agnostic platform for assessing therapy effectiveness.
